

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RICI HEALTHCARE HOLDINGS LIMITED

瑞慈醫療服務控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1526)

VOLUNTARY ANNOUNCEMENT ENTERING INTO THE COOPERATION FRAMEWORK AGREEMENT

This announcement is made by Rici Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, for the purpose of providing shareholders and potential shareholders of the Company the latest information regarding the business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on October 14, 2026, Shanghai Rich Medical Investment Group Co., Ltd. (上海瑞慈醫療投資集團有限公司), an indirect wholly-owned subsidiary of the Company (“**Shanghai Rich Medical**”) entered into a cooperation framework agreement with Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司), a company listed on the Main Board of the Stock Exchange (Stock Code: 2506) (“**Xunfei Healthcare Technology**”) (the “**Cooperation Framework Agreement**”).

THE COOPERATION FRAMEWORK AGREEMENT

Principal terms of the Cooperation Framework Agreement are set out below:

Date: October 14, 2026

Parties: (i) Shanghai Rich Medical
(ii) Xunfei Healthcare Technology

Subject Matter

Pursuant to the Cooperation Framework Agreement, the parties agreed to cooperate in the following areas:

- (i) authorization of Shanghai Rich Medical to utilise certain capabilities of Xunfei Healthcare Technology's Xunfei Spark Medical Model, including but not limited to symptom self-assessment, drug query and report interpretation;
- (ii) interconnectivity of user health data, subject to users' authorization; and
- (iii) exploration of commercialized health management solutions, including joint promotion of health management packages through medical examination business channels and cross-selling of related products and services.

For the avoidance of doubt, the subject matter above is not legally binding, and the parties will separately enter into specific agreements which will set out the specific terms and conditions of the cooperation.

INFORMATION ON THE PARTIES

The Group

The Group is principally engaged in the provision of general hospital services and medical examination services in the People's Republic of China. Headquartered in Shanghai, the Group is a leading private medical examination provider and a comprehensive medical service provider in the Yangtze River Delta. As of June 30, 2026, the Group had a business network covering 28 cities with 1 Class III Grade B general hospital and 80 medical examination centers in operation.

Xunfei Healthcare Technology

Xunfei Healthcare Technology is a leader in China's artificial intelligence healthcare sector, and is committed to becoming an artificial intelligence-powered medical assistant for every doctor and an artificial intelligence-powered health partner for everyone. Leveraging medical large model technology and the construction of a medical knowledge base, Xunfei Healthcare Technology consistently maintains its leading position in medical large models. Xunfei Healthcare Technology has created the artificial intelligence-powered Intelligent Assistant product series and the artificial intelligence-powered Health Partner product series to empower governments, hospitals and patients.

REASONS FOR AND BENEFITS OF ENTERING INTO THE COOPERATION FRAMEWORK AGREEMENT

The Board considers that entering into the cooperation will enable the Group to enhance the user experience in health services, promote the integration of technology with the Group's medical examination and health management businesses, and support the Group's strategic transformation towards a technology-driven medical service provider. The Board is of the view that the entry into of the Cooperation Framework Agreement is in the interests of the Company and its shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Rici Healthcare Holdings Limited
Fang Yixin
Chairman

Shanghai, the PRC, October 15, 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Dr. Fang Yixin, Dr. Mei Hong, Mr. Fang Haoze and Ms. Lin Xiaoying; and three independent non-executive Directors, namely Mr. Jiang Peixing, Ms. Wong Sze Wing and Mr. Tian Wenguo.